

## Poster Programme

### Poster Session 1 Sunday, 18<sup>th</sup> October 2015 at 18:05-19:00

<b>[P1.01]</b>	<b>Evaluation of the frequency of the mutant precore 1896 detected by two different techniques</b> R. Ayari*, I. Sfar, S.J. Ayed, T.B. Abdallah, K. Ayed, Y. Gorgi, <i>Research laboratory of the Immunology of the transplantation and the Immunopathology, Tunisia</i>
<b>[P1.02]</b>	<b>Relation of precore and core promoter mutations with genotypes of hepatitis B virus in Tunisia</b> R. Ayari <sup>*1</sup> , Y. Gorgi <sup>1</sup> , I. Sfar <sup>1</sup> , S.J. Ayed <sup>1</sup> , T. Najjar <sup>2</sup> , K. Ayed <sup>1</sup> , T.B. Abdallah <sup>1</sup> , <sup>1</sup> <i>Charles Nicolle Hospital, Tunisia</i> , <sup>2</sup> <i>Charles Nicolle Hospital, Tunisia</i>
<b>[P1.03]</b>	<b>Immunogenicity of booster vaccination with an aluminum-absorbed hepatitis a vaccine after primary immunization with japanese aluminum-free hepatitis a vaccine</b> S. Fukushima <sup>*1</sup> , T. Nakano <sup>2</sup> , T. Kiyohara <sup>3</sup> , K. Ishii <sup>3</sup> , A. Hamada <sup>1</sup> , <sup>1</sup> <i>Tokyo Medical University Hospital, Japan</i> , <sup>2</sup> <i>Kawasaki Medical University, Japan</i> , <sup>3</sup> <i>National Institute of Infectious Diseases, Japan</i>
<b>[P1.05]</b>	<b>Immunogenicity of zoster vaccine in healthy adults and chronic renal disease patient in Korea accessed by gpEIA kit and IFN-γ ELISpot assay</b> Y. Kim*, J. Hwang, K. Lee, J. Choi, J. Choi, J. Park, C. Lee, H. Kim, H. Park, <i>Yeungnam University, Republic of Korea</i>
<b>[P1.06]</b>	<b>Serotype distribution of invasive group B streptococcal diseases in infants at two university hospitals in Korea</b> H.K. Cho <sup>1</sup> , Y.K. Cho <sup>1</sup> , Y.J. Kim <sup>2</sup> , B.W. Eun <sup>*3</sup> , <sup>1</sup> <i>Gachon University School of Medicine, Republic of Korea</i> , <sup>2</sup> <i>Sungkyunkwan University School of Medicine, Republic of Korea</i> , <sup>3</sup> <i>Eulji University School of Medicine, Republic of Korea</i>
<b>[P1.07]</b>	<b>A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice</b> C.L. Jiang <sup>*1</sup> , L.P. Jiang <sup>1</sup> , R.J. Fan <sup>2</sup> , S.Y. Sun <sup>1</sup> , P.H. Fan <sup>1</sup> , W.H. Su <sup>1</sup> , Y. Zhou <sup>1</sup> , F. Gao <sup>1</sup> , F. Xu <sup>1</sup> , W. Kong <sup>1</sup> , <sup>1</sup> <i>Jilin University, China</i> , <sup>2</sup> <i>Harbin Center for Disease Control and Prevention, China</i>
<b>[P1.08]</b>	<b>Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 env by chimeric live attenuated influenza a virus vaccines</b> C.L. Jiang <sup>*1</sup> , Y. Zang <sup>1</sup> , D.C. Du <sup>1</sup> , N. Li <sup>1</sup> , W.H. Su <sup>1</sup> , Y. Zhou <sup>1</sup> , X.T. Liu <sup>2</sup> , Y. Zhang <sup>1</sup> , Y.C. Wang <sup>3</sup> , W. Kong <sup>1</sup> , <sup>1</sup> <i>Jilin University, China</i> , <sup>2</sup> <i>Changchun University of Technology, China</i> , <sup>3</sup> <i>National Institutes for Food and Drug Control, China</i>
<b>[P1.09]</b>	<b>Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine</b> L. Feng <sup>*1</sup> , Y. Zhang <sup>2</sup> , L. Li <sup>2</sup> , C. Li <sup>2</sup> , C. Sun <sup>1</sup> , P. Li <sup>1</sup> , X. Zheng <sup>1</sup> , Y. Liu <sup>1</sup> , N. Zhong <sup>2</sup> , L. Chen <sup>1,2</sup> , <sup>1</sup> <i>Guangzhou Institutes of Biomedicine and Health, China</i> , <sup>2</sup> <i>The First Affiliated Hospital of Guangzhou Medical University, China</i>
<b>[P1.10]</b>	<b>Inactivated influenza vaccine combined with low toxicity dsRNAs induces mucosal and systemic immunity after intranasal immunization in mice.</b> Y. Ohara <sup>*1,3</sup> , T. Suzuki <sup>1</sup> , T. Nakano <sup>2</sup> , S. Saito <sup>1</sup> , A. Aina <sup>1</sup> , K. Akimoto <sup>3</sup> , H. Hasegawa <sup>1</sup> , <sup>1</sup> <i>National Institute of Infectious Diseases, Japan</i> , <sup>2</sup> <i>Kyowa Hakko bio co., LTD., Japan</i> , <sup>3</sup> <i>Tokyo University of Science, Japan</i>
<b>[P1.11]</b>	<b>Estimating rotavirus vaccine effectiveness in Japan by use of the screening method</b> K. Araki <sup>*1,2</sup> , M. Hara <sup>1</sup> , C. Shimanoe <sup>1</sup> , Y. Nishida <sup>1</sup> , M. Matuo <sup>2</sup> , K. Tanaka <sup>1</sup> , <sup>1</sup> <i>Saga University Saga, Japan</i> , <sup>2</sup> <i>Saga University Saga, Japan</i>
<b>[P1.12]</b>	<b>Recombinant human respiratory syncytial virus G protein expressed in insect cells can defense human respiratory syncytial virus with less immunopathogenic effect.</b> H.S. Lee*, A.R. Kim, H.S. Son, Y.J. Lee, S.S. Kim, Y.J. Kim, <i>Korea National Institute of Health, Republic of Korea</i>
<b>[P1.13]</b>	<b>Seroprevalence of neutralizing antibodies to measles virus in youth Korean: a birth-year cohort analysis</b> Y.W. Han*, D.R. Heo, J.A. Kim, S.J. Kim, S.S. Kim, H.J. Kim, <i>Korea National Institute of Health, Republic of Korea</i>
<b>[P1.14]</b>	<b>Dose sparing of seasonal influenza vaccines in adult and elderly patients - A Randomized, Double-blind, Multi-Center clinical trial</b> Z.V. Vajo <sup>*1</sup> , P.T. Torzsa <sup>2</sup> , L.K. Kalabay <sup>2</sup> , I.J. Jankovics <sup>3</sup> , <sup>1</sup> <i>University of Debrecen, Hungary</i> , <sup>2</sup> <i>Semmelweis University Medical School, Hungary</i> , <sup>3</sup> <i>National Institute of Epidemiology, Hungary</i>
<b>[P1.15]</b>	<b>Quantifying protection against influenza virus infection measured by hemagglutination-inhibition assays in vaccine trials</b> X. Zhao <sup>*1</sup> , V.J. Fang <sup>2</sup> , S.E. Ohmit <sup>3</sup> , A.S. Monto <sup>3</sup> , A.R. Cook <sup>1,4</sup> , B.J. Cowling <sup>2</sup> , <sup>1</sup> <i>National University of Singapore, Singapore</i> , <sup>2</sup> <i>The University of Hong Kong, Hong Kong</i> , <sup>3</sup> <i>University of Michigan School of Public Health, USA</i> , <sup>4</sup> <i>Yale-NUS College, Singapore</i>
<b>[P1.16]</b>	<b>Pertussis outbreak in university students and evaluation of acellular pertussis vaccine effectiveness in Japan</b> M. Hara <sup>*1</sup> , M. Fukuoka <sup>2</sup> , K. Tashiro <sup>1</sup> , I. Ozaki <sup>1</sup> , S. Ohfushi <sup>3</sup> , K. Okada <sup>4</sup> , T. Nakano <sup>5</sup> , W. Fukushima <sup>3</sup> , Y. Hirota <sup>3,6</sup> ,

	<sup>1</sup> Saga University, Japan, <sup>2</sup> Saga-ken Medical Centre Koseikan, Japan, <sup>3</sup> Osaka City University, Japan, <sup>4</sup> Fukuoka Dental College, Japan, <sup>5</sup> Kawasaki Medical School, Japan, <sup>6</sup> Medical Co. LTA, Japan
[P1.17]	<b>Superior protection of microneedle vaccination versus intranasal vaccination against swine-origin influenza A (H1N1) virus infection in mice</b> J.-H. Shin <sup>*1</sup> , J.-K. Park <sup>2</sup> , D.-H. Lee <sup>2</sup> , F.-S. Quan <sup>3</sup> , C.-S. Song <sup>2</sup> , Y.-C. Kim <sup>1</sup> , <sup>1</sup> KAIST, Republic of Korea, <sup>2</sup> Konkuk University, Republic of Korea, <sup>3</sup> Kyung Hee University, Republic of Korea
[P1.18]	<b>Evolutionary analysis and epidemiology of H1N1/2009 virus in Singapore</b> Y.C.F. Su <sup>*1</sup> , U.J. Philip <sup>1</sup> , F.Y. Wong <sup>1</sup> , E.S.C. Koay <sup>2</sup> , L.L.E. Oon <sup>3</sup> , G.J.D. Smith <sup>1</sup> , <sup>1</sup> Duke-NUS Graduate Medical School, Singapore, <sup>2</sup> National University Hospital, Singapore, <sup>3</sup> Singapore General Hospital, Singapore
[P1.19]	<b>Protection against <i>Vibrio vulnificus</i> infection by active and passive immunization with the C-terminal region of the RtxA1/MARTX<sub>Vv</sub> protein</b> T.H. Lee <sup>1</sup> , H.S. Park <sup>1</sup> , J.H. Rhee <sup>2</sup> , K.M. Chung <sup>*1</sup> , <sup>1</sup> Chonbuk National University Medical School, Republic of Korea, <sup>2</sup> Chonnam National University Medical School, Republic of Korea
[P1.20]	<b>A bivalent virus-like particle based vaccine induces a balanced antibody response anginst both enterovirus 71 and norovirus in mice</b> X. Wang <sup>*1</sup> , Z. Ku <sup>1</sup> , W. Dai <sup>1</sup> , T. Chen <sup>1</sup> , X. Ye <sup>1</sup> , C. Zhang <sup>1</sup> , Y. Zhang <sup>2</sup> , Q. Liu <sup>1</sup> , X. Jin <sup>1</sup> , Z. Huang <sup>1</sup> , <sup>1</sup> Chinese Academy of Sciences, China, <sup>2</sup> Shanghai Institutes for Biological Science, China
[P1.21]	<b>Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.</b> S. Shcherbik <sup>1,2</sup> , N. Pearce <sup>1,2</sup> , I. Kiseleva <sup>3</sup> , N. Larionova <sup>3</sup> , L. Rudenko <sup>3</sup> , X. Xu <sup>1</sup> , D. Wentworth <sup>1</sup> , T. Bousse <sup>*1</sup> , <sup>1</sup> Centers for Disease Control and Prevention, USA, <sup>2</sup> Battelle, USA, <sup>3</sup> Institute of Experimental Medicine, Russia
[P1.22]	<b>Oral immunization of a norovirus vaccine leads to superior specific IgA responses in animals</b> L. Kim*, C. Scallan, E. Dora, J. Martinez, K. Hodgson, S. Tucker, Vaxart, Inc, USA
[P1.23]	<b>Impact of a nasal mucoadhesive excipient, carboxy-vinyl polymer, on enhancement of immune responses induced by intranasal administration of an inactivated influenza vaccine</b> S. Saito <sup>*1,3</sup> , A. Ainai <sup>1</sup> , T. Suzuki <sup>1</sup> , N. Harada <sup>2</sup> , S. Tamura <sup>1</sup> , Y. Yuki <sup>4</sup> , H. Takeyama <sup>3</sup> , H. Tsukada <sup>2</sup> , H. Kiyono <sup>4</sup> , H. Hasegawa <sup>1</sup> , <sup>1</sup> National Institute of Infectious Diseases, Japan, <sup>2</sup> Hamamatsu Photonics K.K., Japan, <sup>3</sup> Waseda University, Japan, <sup>4</sup> University of Tokyo, Japan
[P1.24]	<b>Strong induction of nasal IgA antibodies after intranasal vaccination among mice primed by preceding infection</b> A. Ainal*, K. Ikeda, R. Ito, T. Suzuki, S.-I. Tamura, T. Odagiri, M. Tashiro, H. Asanuma, H. Hasegawa, National Institute of Infectious Diseases, Japan
[P1.25]	<b>Development of subunit vaccines against human dengue viruses</b> M. Li, J. Sun, P. Hao, J. Xia*, Institut Pasteur of Shanghai, China
[P1.26]	<b>Acute encephalitis and encephalopathy associated with vaccine preventable diseases in children, Japan, 2006-2013</b> H. Okuno*, T. Sunagawa, S. Morino, H. Satoh, S. Arai, K. Oishi, K. Tanaka-Taya, National Institute of Infectious Diseases, Japan
[P1.27]	<b>The immunodominance change and protection of CD4<sup>+</sup> T cell responses elicited by an envelope protein domain III-based tetravalent dengue vaccine in mice</b> S.H. Wu*, H.M. Hu, Y.J. Hsiao, C.K. Wu, H.S. Chung, C.H. Pan, National Health Research Institute, Taiwan
[P1.28]	<b>A novel strategy combining advantages of DNA vaccine and virus like particle for efficient influenza vaccine</b> K-W. Seo*, E.Y. Jang, M-S. Lee, J. Cho, H. Yi, Centers for Disease Control and Prevention, Republic of Korea
[P1.29]	<b>Generation of genetically modified H5N8 avian influenza A vaccine candidates by plasmid based reverse genetics</b> E.Y. Jang*, M-S. Lee, K-W. Seo, J. Cho, K. Kim, H. Yi, Centers for Disease Control and Prevention, Republic of Korea
[P1.30]	<b>Non-invasive universal influenza vaccine based on adenovirus vector</b> E.H. Kim <sup>*1</sup> , G.Y. Han <sup>1</sup> , M.K. Song <sup>1</sup> , A. Pereboev <sup>1,2</sup> , J.S. Hong <sup>1,3</sup> , H.H. Nguyen <sup>1</sup> , <sup>1</sup> International Vaccine Institute, Republic of Korea, <sup>2</sup> University of Alabama, USA, <sup>3</sup> University of Alabama, USA
[P1.31]	<b>Investigation of ifn-γ response to the inactivated vaccine developed against crimean-congo hemorrhagic fever virus</b> E. Berber, N. Canakoglu, I. Sozdutmaz, M. Caliskan, A. Ozdarendeli*, Erciyes University Vaccine Research and Development Center, Turkey
[P1.32]	<b>Attenuated vaccinia virus expressing M2-1 as a Promising Vaccine candidate against Human respiratory syncytial virus</b> A.R. Kim*, H.S. Lee, H.S. Son, Y.J. Lee, S.S. Kim, Y.J. Kim, Korea National Institute of Health, Republic of Korea
[P1.33]	<b>Passive immunity to measles, mumps and rubella in Korea infants during the first year of life</b> S.J. Kim*, H.J. Kang, H.E. Eom, Y.J. Park, J.G. Nam, S.S. Kim, Korea National Institute of Health, Republic of Korea

[P1.34]	<b>Glycoprotein B-specific monoclonal antibody prevents HSV-induced ocular diseases</b> A. Krawczyk <sup>*1</sup> , M. Dirks <sup>1</sup> , A. Buch <sup>4</sup> , U. Dittmer <sup>1</sup> , L. Bagnewski <sup>2</sup> , M. Busch <sup>2</sup> , B. Sodeik <sup>4</sup> , A. Heiligenhaus <sup>2</sup> , M. Roggendorf <sup>1</sup> , D. Bauer <sup>2</sup> , <sup>1</sup> Institute of Virology, Germany, <sup>2</sup> Department of Ophthalmology at St. Franziskus Hospital, Germany, <sup>3</sup> Institute of Virology, Germany, <sup>4</sup> Hannover Medical School, Germany
[P1.35]	<b>Development of neutralizing assay using pseudotype virus with Middle East Respiratory Syndrome Coronavirus(MERS-CoV) spike protein</b> S.H. Park*, S.S. Kim, J.G. Nam, J.S. Yang, Korea National Institute of Health, Republic of Korea
[P1.36]	<b>Cold-adapted pandemic 2009 H1N1 influenza live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses</b> Y.H. Jang*, Y.H. Byun, Y.J. Lee, Y.H. Lee, K.H. Lee, B.L. Seong, Yonsei university, Republic of Korea
[P1.37]	<b>Activation of cryptic epitopes in the hemagglutinin as a rational design of a cross-protective influenza live vaccine</b> Y.J. Lee <sup>*1</sup> , Y.J. Lee <sup>1</sup> , P. Kim <sup>1</sup> , Y.H. Jang <sup>1</sup> , B.L. Seong <sup>1,2</sup> , <sup>1</sup> Yonsei Univ, Republic of Korea, <sup>2</sup> Vaccine Translational Research Center, Republic of Korea
[P1.38]	<b>Study on the production of HA antigen reagent for quality control of pandemic influenza vaccine</b> H.J. Oh <sup>1</sup> , Y.J. Choi <sup>*1</sup> , S.K. Chang <sup>1</sup> , H.J. Chung <sup>1</sup> , N.R. Lee <sup>1</sup> , H.S. Moon <sup>1</sup> , D.H. Kim <sup>1</sup> , J.Y. Hong <sup>1</sup> , M.S. Yang <sup>1</sup> , D.K. Kim <sup>2</sup> , <sup>1</sup> National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Korea, <sup>2</sup> National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Korea
[P1.39]	<b>Emergence and characterization of vaccine variants for influenza B viruses in Korea from 2001 to 2012</b> J.Y. Lee*, J.H. Choi, D. Kwon, W.Y. Choi, J.S. Kim, M.S. Kim, N.J. Lee, K. Kim, C. Kang, Korea Centers for Disease Control and Prevention, Republic of Korea
[P1.40]	<b>Synthetic nucleic acid antibody prophylaxis confers protective immunity in vivo against Chikungunya virus infection</b> K. Muthumanji <sup>*1</sup> , N.Y. Sardesai <sup>2</sup> , J.J. Kim <sup>2</sup> , K.E. Ugen <sup>3</sup> , D. Weiner <sup>1</sup> , <sup>1</sup> University of Pennsylvania School of Medicine, USA, <sup>2</sup> Inovio Pharmaceuticals Inc., USA, <sup>3</sup> University of South Florida Morsani College of Medicine, USA
[P1.41]	<b>Protective efficacy of trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 master donor strains</b> Y.H. Jang*, Y.H. Byun, Y.J. Lee, Y.H. Lee, K.H. Lee, J. Lee, B.L. Seong, Yonsei university, Republic of Korea
[P1.42]	<b>Immediate and broad spectrum protection against heterotypic influenza and respiratory syncytial virus infection by a live attenuated influenza vaccine</b> Y.J. Lee <sup>*1</sup> , J.Y. Lee <sup>2</sup> , J. Chang <sup>2</sup> , B.L. Seong <sup>1,3</sup> , <sup>1</sup> Yonsei Univ, Republic of Korea, <sup>2</sup> Ewha Womans Univ, Republic of Korea, <sup>3</sup> Vaccine Translational Research Center, Republic of Korea
[P1.43]	<b>X-31 cold-adapted live attenuated influenza vaccines provides universal protection against hemagglutinin group 1 and 2 influenza A viruses</b> Y.H. Jang*, Y.J. Lee, Y.H. Byun, B.L. Seong, Yonsei university, Republic of Korea
[P1.44]	<b>Apoptosis-triggered attenuation of a viral virulence for rational design of a live attenuated vaccine</b> Y.H. Jang*, Y.H. Byun, K.H. Lee, Y.H. Lee, Y.J. Lee, J. Lee, B.L. Seong, Yonsei university, Republic of Korea
[P1.45]	<b>Genetic and phenotypic analysis of attenuation markers from X-31 cold-adapted live attenuated influenza vaccine donor strain</b> Y.H. Jang*, Y.H. Byun, K.H. Lee, B.L. Seong, Yonsei university, Republic of Korea
[P1.46]	<b>Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45</b> P. Vijayachari <sup>1</sup> , K. Vedhagiri <sup>1</sup> , K. Mallilankaraman <sup>2</sup> , P.P. Mathur <sup>3</sup> , N.Y. Sardesai <sup>5</sup> , D.B. Weiner <sup>1</sup> , K.E. Ugen <sup>4</sup> , K. Muthumanji <sup>*1</sup> , <sup>1</sup> Indian Council of Medical Research, India, <sup>2</sup> University of Pennsylvania School of Medicine, USA, <sup>3</sup> KIIT University, India, <sup>4</sup> University of South Florida Morsani College of Medicine, USA, <sup>5</sup> Inovio Pharmaceuticals Inc, USA
[P1.47]	<b>Cross-H5 and cross-subtypic protective antibody responses against diverse influenza A viruses elicited with a heterologous DNA and virus-like particle prime-boost vaccination</b> G.Q. Wang <sup>*1</sup> , P. Zhou <sup>1</sup> , H.H. Ren <sup>1</sup> , P. Buchy <sup>2</sup> , G.H. Cheng <sup>3</sup> , V. Deubel <sup>1</sup> , <sup>1</sup> Chinese Academy of Sciences, China, <sup>2</sup> Institut Pasteur in Cambodia, Cambodia, <sup>3</sup> University of California, USA
[P1.48]	<b>Investigation of ifn-γ response to the inactivated vaccine developed against crimean-congo hemorrhagic fever virus</b> E. Berber*, I. Sozdutmaz, N. Canakoglu, M. Caliskan, A. Ozdarendeli, Erciyes University Vaccine Research and Development Center, Turkey
[P1.49]	<b>Study on the production of HA antigen reagent for quality control of pandemic influenza vaccine</b> H.J. Oh <sup>1</sup> , Y.J. Choi <sup>*1</sup> , S.K. Chang <sup>1</sup> , H.J. Chung <sup>1</sup> , N.R. Lee <sup>1</sup> , D.H. Kim <sup>1</sup> , J.Y. Hong <sup>1</sup> , M.S. Yang <sup>1</sup> , D.K. Kim <sup>2</sup> , H.S. Moon <sup>1</sup> , <sup>1</sup> National Institute of Food and Drug Safety Evaluation, Republic of Korea, <sup>2</sup> National Institute of Food and Drug Safety Evaluation, Republic of Korea
[P1.51]	<b>Indonesia: current situation 2015 and preparedness toward end game polio eradication</b> J. Sundoro <sup>*1</sup> , S.R. Hadinegoro <sup>1</sup> , <sup>1</sup> Indonesian Technical Advisory Group on Immunization, Indonesia, <sup>2</sup> Indonesian

	<i>Technical Advisory Group on Immunization, Indonesia</i>
[P1.52]	<b>Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine</b> S.H. Hong* <sup>1,3</sup> , S.E. Lee <sup>1,3</sup> , C.T. Nguyen <sup>2,3</sup> , S.Y. Kim <sup>2,3</sup> , T.T. Nguyen <sup>2,3</sup> , J.H. Rhee <sup>2,3</sup> , <sup>1</sup> <i>Chonnam National University, Republic of Korea</i> , <sup>2</sup> <i>Chonnam National University Medical School, Republic of Korea</i> , <sup>3</sup> <i>Clinical Vaccine R&amp;D Center, Republic of Korea</i>
[P1.53]	<b>Designing and improving vaccines in silico with iVAX toolkit</b> F. Terry <sup>1</sup> , G. Richard <sup>1</sup> , R. Martin <sup>1</sup> , J. Tivin <sup>1</sup> , L. Moise <sup>1,2</sup> , W. Martin <sup>1</sup> , A.S. De Groot* <sup>1,2</sup> , <sup>1</sup> <i>EpiVax, Inc., USA</i> , <sup>2</sup> <i>University of Rhode Island, USA</i>
[P1.54]	<b>Better vaccine design by avoiding regulatory T cell immuno-evasion triggers</b> F. Terry <sup>1</sup> , A. Gutierrez <sup>2</sup> , R. Liu <sup>2</sup> , R. Tassone <sup>2</sup> , S. Gregory <sup>2</sup> , P. Losikoff <sup>3</sup> , C. Bailey-Kellogg <sup>4</sup> , L. Moise <sup>1,2</sup> , W. Martin <sup>1</sup> , A.S. De Groot* <sup>1,2</sup> , <sup>1</sup> <i>EpiVax, Inc., USA</i> , <sup>2</sup> <i>University of Rhode Island, USA</i> , <sup>3</sup> <i>Rhode Island Hospital and the Warren Alpert Medical School at Brown University, USA</i> , <sup>4</sup> <i>Dartmouth College, USA</i>
[P1.55]	<b>Lack of T cell epitope conservation may explain limited efficacy of RTS,S vaccine against malaria</b> A.H. Gutierrez <sup>1</sup> , R. Tassone <sup>1</sup> , L. Levitz <sup>2</sup> , J.J. Juliano <sup>2</sup> , S. Meshnick <sup>2</sup> , F. Terry <sup>3</sup> , W. Martin <sup>3</sup> , A.S. De Groot* <sup>1,3</sup> , <sup>1</sup> <i>University of Rhode Island, USA</i> , <sup>2</sup> <i>University of North Carolina at Chapel Hill, USA</i> , <sup>3</sup> <i>EpiVax, Inc., USA</i>
[P1.56]	<b>Parasite antigenic diversity and host genetic factors imply uphill battle for RTS,S malaria vaccine</b> F. Terry <sup>1</sup> , L. Levitz <sup>2</sup> , S. Meshnick <sup>2</sup> , J. Juliano <sup>2</sup> , G. Tegha <sup>3</sup> , A. Gutierrez <sup>4</sup> , R. Tassone <sup>4</sup> , W. Martin <sup>1</sup> , A.S. De Groot* <sup>1,4</sup> , <sup>1</sup> <i>EpiVax, Inc., USA</i> , <sup>2</sup> <i>University of North Carolina, USA</i> , <sup>3</sup> <i>UNC Project, Malawi</i> , <sup>4</sup> <i>University of Rhode Island, USA</i>
[P1.58]	<b>Development of a broadly protective Shigella vaccine</b> M.J. Kim*, S. Rho, H. Kim, S.Y. Lee, M.K. Song, D.W. Kim, C. Cerkinsky, J-O. Kim, <i>International Vaccine Institute, Republic of Korea</i>
[P1.59]	<b>HIV antigens linked to selected clones of anti-human CD40 antibodies in combination to CD40L induce strong CD8+ T cell responses in vitro</b> M. Montes* <sup>1</sup> , S. Zurawski <sup>1</sup> , A.L. Flamar <sup>1</sup> , Z. Wang <sup>1</sup> , A. O'Bar <sup>1</sup> , C. Beauregard <sup>1</sup> , Y. Levy <sup>1</sup> , G. Zurawski <sup>1</sup> , <sup>1</sup> <i>Baylor Institute for Immunology Research, USA</i> , <sup>2</sup> <i>Vaccine Research Institute, France</i>
[P1.60]	<b>Dengue vaccine R&amp;D: challenges and opportunities</b> D. Casimiro* <sup>1</sup> , B.A. Coller <sup>1</sup> , S. Whitehead <sup>2</sup> , A. Durbin <sup>3</sup> , <sup>1</sup> <i>Merck Research Laboratories, USA</i> , <sup>2</sup> <i>National Institutes of Health, USA</i> , <sup>3</sup> <i>Johns Hopkins University, USA</i>
[P1.61]	<b>Development of alternative test method of potency and identity for fast release of smallpox vaccine</b> D.H. Kim*, Y.T. Kim, H.J. Chung, S.B. Shim, N.R. Lee, S.M. Lee, J.H. Jeong, S.K. Chang, Y.J. Choi, H.J. Oh, <i>Ministry of Food and Drug Safety(MFDS), Republic of Korea</i>
[P1.62]	<b>Plant-made virus-like particles bearing influenza hemagglutinin elicit a rapid and robust innate immune response in vitro</b> H. Hendin* <sup>1</sup> , S. Pillet <sup>2,3</sup> , T. Talarico <sup>4</sup> , N. Charland <sup>3</sup> , M.A. D'Aoust <sup>3</sup> , N. Landry <sup>3</sup> , B.J. Ward <sup>2,3</sup> , <sup>1</sup> <i>McGill University, Canada</i> , <sup>2</sup> <i>Research Institute of the McGill University Health Centre, Canada</i> , <sup>3</sup> <i>Medicago Inc., Canada</i> , <sup>4</sup> <i>Medicago USA, USA</i>
[P1.63]	<b>Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in adolescent girls in Korea, with the new 2-dose schedule</b> H. Lee* <sup>1</sup> , B.G. Kim <sup>2</sup> , S. Hur <sup>3,4</sup> , H. Jang <sup>5</sup> , I-H. Lee <sup>6</sup> , W-Y. Sohn <sup>6</sup> , G. Van Kriekinge <sup>7</sup> , <sup>1</sup> <i>Seoul National University Bundang Hospital, Republic of Korea</i> , <sup>2</sup> <i>Sungkyunkwan University School of Medicine, Republic of Korea</i> , <sup>3</sup> <i>Seoul St. Mary's Hospital, Republic of Korea</i> , <sup>4</sup> <i>The Catholic University of Korea, Republic of Korea</i> , <sup>5</sup> <i>GSK Vaccines, Republic of Korea</i> , <sup>6</sup> <i>GSK Vaccines, Singapore</i> , <sup>7</sup> <i>GSK Vaccines, Belgium</i>
[P1.64]	<b>Screen HCV genotype-specific epitope polypeptides based on conserved sequences assessment in HCV E2 region and B-cell epitope prediction</b> X. Gong*, L.X. Qi, R. Hua, Y.M. Shan, <i>Jilin University, China</i>
[P1.65]	<b>Immunogenicity of virus-like particles containing Toxoplasma gondii inner membrane complex protein</b> D-H. Lee, S-H. Lee, A-R. Kim, F-S. Quan*, <i>Kyung Hee University, Republic of Korea</i>
[P1.66]	<b>A Structure Based Approach to Engineering Contraceptive Vaccine Antigens</b> D. Basore* <sup>1</sup> , R. Naz <sup>2</sup> , S. Michale <sup>3</sup> , S. Isern <sup>3</sup> , B. Wright <sup>1</sup> , K. Saporita <sup>1</sup> , D. Crone <sup>1</sup> , C. Bystroff <sup>1</sup> , <sup>1</sup> <i>Rensselaer Polytechnic Institute, USA</i> , <sup>2</sup> <i>West Virginia University, USA</i> , <sup>3</sup> <i>Florida Gulf Coast University, USA</i>

**Poster Session 2**  
**Monday, 19<sup>th</sup> October 2015, 15:00-16:00**

[P2.01]	<b>Immunization intranasal with 37 kda protein of naegleria fowleri in association with cholera toxin reduces mortality after infection in mice</b> M. Carrasco-Yepez*, G. Perez-Lozano <sup>1</sup> , J. Perez-Lopez <sup>2</sup> , A. Contis <sup>2</sup> , D. Castillo-Ramirez <sup>1</sup> , P. Bonilla-Lemus <sup>1</sup> , R.
---------	--

	Campos-Rodriguez <sup>2</sup> , S. Rojas-Hernandez <sup>2</sup> , <sup>1</sup> <i>National Autonomous University of Mexico, Mexico, <sup>2</sup>Institute Polytechnic, Mexico</i>
[P2.02]	<b>Evaluation of botulinum neurotoxin A non-toxic derivatives as an alternative antigens for antitoxin production</b> A.B. David*, E. Diamant, A. Torgeman, A. Barnea, O. Rosen, A. Schwarz, E. Ozeri, R. Zichel, <i>IIBR, Israel</i>
[P2.03]	<b>Involvement of Fc fragment in neutralizing activity of anti-botulinum polyclonal and monoclonal antibodies</b> A. Torgeman*, E. Ozeri, E. Diamant, A. Ben David, O. Rosen, A. Barnea, A. Makovitzki, R. Zichel, <i>IIBR, Israel</i>
[P2.04]	<b>Limited cross-protective immunity against West Nile Virus by live attenuated Japanese encephalitis vaccine SA 14-14-2</b> P. Chowdhury*, J. Borah, P. Chowdhury, S.A. Khan, <i>Indian Council of Medical Research, India</i>
[P2.05]	<b>Detection of antibodies against orally administered candida antigens in mouse sera using ELISA method.</b> J. Nepereny*, V. Vrzal, <i>Bioveta, a.s., Czech Republic</i>
[P2.06]	<b>Enhanced antigen specific B cell responses elicited by HIV-1 gp120 DNA prime and protein boost vaccines</b> H. Li <sup>1</sup> , K. Hollister <sup>2</sup> , L. Zhang <sup>3</sup> , Y. Chen <sup>1</sup> , D. Farfan <sup>1</sup> , W. Li <sup>1</sup> , A. Dent <sup>2</sup> , S. Lu <sup>1,3</sup> , S. Wang* <sup>1</sup> , <sup>1</sup> <i>University of Massachusetts Medical School, USA, <sup>2</sup>Indiana University School of Medicine, USA, <sup>3</sup>The First Affiliated Hospital, Nanjing Medical University, China</i>
[P2.07]	<b>Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer</b> S.H. Hong* <sup>1,2</sup> , V. Verma <sup>1,3</sup> , Y.S. Lee <sup>1,2</sup> , N.T.M. Duong <sup>1,3</sup> , K.J. Jeong <sup>1,3</sup> , Y.C. Sung <sup>4</sup> , J.T. Lee <sup>5</sup> , S.E. Lee <sup>1,2</sup> , J.H. Rhee <sup>1,3</sup> , <sup>1</sup> <i>Chonnam National University, Republic of Korea, <sup>2</sup>School of Dentistry, Republic of Korea, <sup>3</sup>Chonnam National University Medical School, Republic of Korea, <sup>4</sup>POSTECH, Republic of Korea, <sup>5</sup>Kyungpook National University School of Medicine, Republic of Korea</i>
[P2.08]	<b>Direct administration of alum into the airway promotes lymphoid cluster formation in the lung</b> E. Kuroda* <sup>1</sup> , K.J. Ishii <sup>1</sup> , <sup>1</sup> <i>Osaka University, Japan, <sup>2</sup>National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan</i>
[P2.09]	<b>Norovirus (NoV) specific protective immune responses induced by recombinant P domain based vaccine are potently enhanced by mucosal adjuvant FlaB</b> V. Verma <sup>1</sup> , P. Sao* <sup>1</sup> , S.E. Lee <sup>1,2</sup> , J.H. Rhee <sup>1,3</sup> , <sup>1</sup> <i>Chonnam National University Medical School, Republic of Korea, <sup>2</sup>Chonnam National University, Republic of Korea, <sup>3</sup>Chonnam National University Medical School, Republic of Korea</i>
[P2.10]	<b>Modification of recombinant poxvirus vectors to generate more immunogenic vaccines against avian influenza in poultry</b> S. Ascough, <i>The Pirbright Institute, UK</i>
[P2.11]	<b>Effect of intranasal immunization with cholera toxin and total extract of naegleria fowleri in the production of cytokines in spleen, nalt, nasal passages and cervical nodules as well as activation of dendritic cells and macrophages in the map model in balb/ c mice</b> S.A.R. Osornio* <sup>1</sup> , M.C.P. Juarez <sup>1</sup> , M. CARRASCO YEPEZ <sup>2</sup> , O. CASTILLO RODRIGUEZ <sup>1</sup> , A. RESENDIZ ALBOR <sup>1</sup> , I. ARGINIEGA <sup>1</sup> , R. CAMPOS RODRIGUEZ <sup>1</sup> , S. ROJAS HERNANDEZ <sup>1</sup> , <sup>1</sup> <i>Instituto Politecnico Nacional, Mexico, <sup>2</sup>Universidad Nacional Autonoma de Mexico, Mexico</i>
[P2.12]	<b>Intranasal immunization with membrane fractions of N. fowleri or N. lovaniensis induces protection in the model of the meningitis produced by N. fowleri in mice</b> J.A.P. Lopez* <sup>1</sup> , M.C. Yepez <sup>2</sup> , R.C. Rodriguez <sup>1</sup> , A.C. Montes de Oca <sup>1</sup> , P.B. Lemus <sup>1,2</sup> , D.A.C. Ramirez <sup>1</sup> , S.R. Hernandez <sup>1</sup> , <sup>1</sup> <i>Instituto Politecnico Nacional, Mexico, <sup>2</sup>UIICSE, UNAM FES Iztacala, Mexico</i>
[P2.13]	<b>New insights into the cellular immune response on C. trachomatis and C. suis infection in pigs</b> T. Käser* <sup>1</sup> , J.A. Pasternak <sup>1</sup> , M. Rieder <sup>1</sup> , G. Hamonic <sup>1</sup> , K. Lai <sup>1</sup> , H.L. Wilson <sup>1</sup> , V. Gerds <sup>1</sup> , F. Meurens <sup>1</sup> , <sup>1</sup> <i>VIDO-InterVac, Canada, <sup>2</sup>LUNAM University, France, <sup>3</sup>INRA, France</i>
[P2.14]	<b>Suboptimal influenza vaccination results in enhanced numbers of pulmonary macrophages upon influenza challenge in mice</b> M. Schotsaert*, A. Garcia-Sastre, <i>Icahn School of Medicine at Mount Sinai, USA</i>
[P2.15]	<b>Bacterial expression and assembly of recombinant human papillomavirus type 16 L1 virus-like particle and the evaluation of immunogenicity in mice</b> J.E. Yu* <sup>1,2</sup> , Y.J. Lee <sup>1,2</sup> , B.L. Seong <sup>1,2</sup> , <sup>1</sup> <i>Yonsei university, Republic of Korea, <sup>2</sup>Vaccine Translational Research Center, Republic of Korea</i>
[P2.16]	<b>Green tea catechin-inactivated viral vaccine</b> Y.H. Lee* <sup>1</sup> , Y.J. Lee <sup>1</sup> , Y.J. Lee <sup>1</sup> , J.H. Lee <sup>1</sup> , B.L. Seong <sup>1,2</sup> , <sup>1</sup> <i>Yonsei University, Republic of Korea, <sup>2</sup>Vaccine Translational Research Center, Republic of Korea</i>
[P2.17]	<b>Production and purification of virus like particle (VLP) based Hepatitis C vaccine candidate</b> C. Peixoto <sup>1</sup> , A. Coroadinha <sup>1</sup> , R. Silva <sup>1</sup> , R. Castro <sup>1</sup> , P. Alves <sup>1</sup> , M. Carrondo <sup>1</sup> , A. Xenopoulos <sup>2</sup> , P. Pattnaik* <sup>3</sup> , <sup>1</sup> <i>Instituto de Biologia Experimental e Tecnológica, Portugal, <sup>2</sup>EMD Millipore Corporation, USA, <sup>3</sup>Merck Pte Ltd, Singapore</i>
[P2.18]	<b>Strategies for introducing Japanese encephalitis vaccine in the national immunization program: Asia-Pacific region</b>

	C.E. Dacula <sup>*1,2</sup> , S.A. Costa-Clemens <sup>3</sup> , <sup>1</sup> <i>University of Siena, Italy</i> , <sup>2</sup> <i>Far Eastern University-NRMF, The Philippines</i> , <sup>3</sup> <i>Novartis Vaccines Academy, Italy</i>
[P2.19]	<b>Tolerance to frameshift mutations in HA cleavage site as a mechanism for highly pathogenic H5N1 viruses.</b> Y.J. Lee <sup>*1,2</sup> , J.H. Lee <sup>2</sup> , S.B. Kwon <sup>2</sup> , Y.H. Lee <sup>2</sup> , Y.H. Jang <sup>2</sup> , K.H. Lee <sup>2</sup> , B.L. Seong <sup>1,2</sup> , <sup>1</sup> <i>Yonsei University, Republic of Korea</i> , <sup>2</sup> <i>Yonsei University, Republic of Korea</i> , <sup>3</sup> <i>Yonsei University, Republic of Korea</i>
[P2.20]	<b>Sociocultural determinants of anticipated acceptance and actual uptake of pandemic influenza vaccines in Pune, India: a community study using mixed-methods</b> N. Sundaram <sup>*1,3</sup> , V. Purohit <sup>2,5</sup> , C. Schaetti <sup>1,3</sup> , L. Grize <sup>1,3</sup> , S. Joseph <sup>2,5</sup> , C. Schindler <sup>1,3</sup> , A. Kudale <sup>2,5</sup> , M.G. Weiss <sup>1,3</sup> , <sup>1</sup> <i>Swiss Tropical and Public Health Institute, Switzerland</i> , <sup>2</sup> <i>Maharashtra Association of Anthropological Sciences, India</i> , <sup>3</sup> <i>University of Basel, Switzerland</i> , <sup>4</sup> <i>National University of Singapore, Singapore</i> , <sup>5</sup> <i>Savitribai Phule Pune University, India</i>
[P2.21]	<b>Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin</b> Y.J. Lee <sup>*1,2</sup> , Y.H. Jang <sup>1,2</sup> , P. Kim <sup>1,2</sup> , Y.H. Lee <sup>1,2</sup> , Y.H. Byun <sup>1</sup> , K.H. Lee <sup>1,2</sup> , B.L. Seong <sup>1,2</sup> , <sup>1</sup> <i>Yonsei University, Republic of Korea</i> , <sup>2</sup> <i>Yonsei University, Republic of Korea</i>
[P2.22]	<b>Knock out of PB1-F2 for enhanced safety of cold-adapted live attenuated influenza vaccine</b> Y.H. Byun <sup>*1</sup> , Y.H. Jang <sup>1</sup> , Y.J. Lee <sup>1</sup> , Y.H. Lee <sup>1</sup> , J.H. Lee <sup>1</sup> , Y.J. Lee <sup>1</sup> , B.J. Hwang <sup>2</sup> , H.J. Choi <sup>1</sup> , K.H. Lee <sup>1</sup> , B.L. Seong <sup>1,3</sup> , <sup>1</sup> <i>Yonsei University, Republic of Korea</i> , <sup>2</sup> <i>Konkuk University, Republic of Korea</i> , <sup>3</sup> <i>Vaccine Translation Research Center, Republic of Korea</i>
[P2.23]	<b>Comparative post-licensure safety surveillance study of human papillomavirus vaccines in healthy Mumbai women</b> V.C. Sangar <sup>*1</sup> , B.B. Ghongane <sup>1</sup> , R. Gupte <sup>2</sup> , A. Chowdhary <sup>3</sup> , <sup>1</sup> <i>B. J. Govt. Medical College and Sassoon General Hospital, India</i> , <sup>2</sup> <i>Gupte Maternity and Surgical Home, India</i> , <sup>3</sup> <i>Haffkine Institute for Training, Research and Testing, India</i>
[P2.24]	<b>TLR7 agonist increases the safety and efficacy of attenuated West Nile Virus NS4B P38G mutant vaccination in old mice</b> T. Wang*, G. Xie, H. Luo, B.H. Peng, E. Winkelmann, A.D. Barrett, <i>University of Texas Medical Branch, USA</i>
[P2.25]	<b>Safety profile following pentavalent immunization in Indonesian infants: post marketing surveillance phase IV</b> J. Sundoro*, H.I. Satari, S.R. Hadinegoro, K. Rusmil, I.G.G. Djelantik, A. Arhana, M.N. Sitaresmi, S. B. Novilia, <i>Indonesian Technical Advisory Group on Immunization, Indonesia</i>
[P2.26]	<b>Safety profile of synthetic hemozoin as vaccine adjuvant</b> M.S.J. Lee <sup>*1</sup> , Y. Igari <sup>2</sup> , T. Tsukui <sup>2</sup> , S. Akira <sup>1</sup> , K.J. Ishii <sup>1,3</sup> , C. Coban <sup>1</sup> , <sup>1</sup> <i>Immunology Frontier Research Center, Japan</i> , <sup>2</sup> <i>ZENOAQ – Nippon Zenyaku Kogyo Co. Ltd, Japan</i> , <sup>3</sup> <i>National Institute of Biomedical Innovation, Japan</i>
[P2.27]	<b>A new approach to antigen delivery using the nanoparticle templating system</b> A.C. Taki*, P.M. Smooker, <i>RMIT University, Australia</i>
[P2.28]	<b>Development of a Newcastle disease virus vaccine vector expressing a foreign gene through an internal ribosomal entry site</b> Q. Yu <sup>*1</sup> , Z. Zhang <sup>1,2</sup> , W. Zhao <sup>1,3</sup> , D.S. Li <sup>2</sup> , J. Yang <sup>1,4</sup> , L. Zsak <sup>1</sup> , <sup>1</sup> <i>US National Poultry Research Center, USA</i> , <sup>2</sup> <i>Northeast Agricultural University, China</i> , <sup>3</sup> <i>Beijing Centre for Disease Control and Prevention, China</i> , <sup>4</sup> <i>Chongqing Academy of Animal Sciences, China</i>
[P2.29]	<b>Application of HP-beta-CD for mucosal adjuvant</b> T. Kusakabe <sup>*1,2</sup> , E. Kuroda <sup>2</sup> , K.J. Ishii <sup>1,2</sup> , <sup>1</sup> <i>Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan</i> , <sup>2</sup> <i>Osaka University, Japan</i>
[P2.30]	<b>Chitosan as an immunomodulating agent in HSV-1 infection mouse model</b> B. Choi, M. Anower, D. Jo, H. Sayeed, C. Joung, S. Sohn*, <i>Ajou University, Republic of Korea</i>
[P2.31]	<b>Novel strategies to enhance the antigenic specificity of a measles virus vaccine vector</b> J. Reyes-del Valle*, I. Ceballos-Olvera, E. Julik, R. Abdelgalel, I.S. Harahap-Carrillo, A. Huff, <i>School of Life Sciences, USA</i>
[P2.32]	<b>Characterization of CpG-ODN motifs and swine Toll-like receptor 9 interaction in HEK293T model system</b> J-N. Chi*, Y-H. Tsao, H-P. Liu, M-S. Chien, C. Huang, <i>National Chung Hsing University, Taiwan</i>
[P2.33]	<b>Synthetic nanofiber vaccines for the induction of multifunctional CD8+ T cell populations in the respiratory mucosa</b> C.B. Chesson <sup>*1</sup> , R.J. Nusbaum <sup>1</sup> , J.J. Endsley <sup>1</sup> , A. Zloza <sup>2</sup> , J.S. Rudra <sup>1</sup> , <sup>1</sup> <i>University of Texas Medical Branch, USA</i> , <sup>2</sup> <i>Rutgers University Cancer Institute, USA</i>
[P2.34]	<b>Enhanced CTL vaccination by prolonged binding of XCL1 fusion proteins at the injection site</b> V.P. Panagiotou <sup>*1</sup> , G.D. Diaceri <sup>1</sup> , X.Q. Quaglia <sup>1</sup> , J.A.H. Hubbell <sup>1,2</sup> , <sup>1</sup> <i>School of Life Sciences and School of Engineering Ecole Polytechnique Fédérale de Lausanne, Switzerland</i> , <sup>2</sup> <i>The University of Chicago, USA</i>
[P2.35]	<b>Hepatic targeting of vaccine antigens</b> V.P. Panagiotou <sup>*1</sup> , G.D. Diaceri <sup>1</sup> , X.Q. Quaglia <sup>1</sup> , J.A.H. Hubbell <sup>1,2</sup> , <sup>1</sup> <i>School of Life Sciences and School of</i>

	<i>Engineering Ecole Polytechnique Fédérale de Lausanne, Switzerland, <sup>2</sup>The University of Chicago, USA</i>
[P2.36]	<b>Size effects of GNP vaccines on induction of cellular immune response toward cancer immunotherapy</b> S. Kang*, S. Ahn, J. Lee, E-C. Shin, S. Jon, KAIST, Republic of Korea
[P2.37]	<b>Chitosan-g-poly(lactide) copolymer as an effective adjuvant for the subunit vaccine against infectious bursal disease</b> P-F. Hsieh*, G-F. Chen, M-Y. Liao, M-K. Hsieh, National Chung Hsing University, Taiwan
[P2.38]	<b>Mucosal and systemic immune response of Ctenopharyngodon idella to immunization with an antigenic preparation of vaccine candidate Aeromonas hydrophila strain</b> S.S. Giri <sup>*1</sup> , C. Chi <sup>1</sup> , H.J. Kim <sup>1</sup> , S-K. Yoon <sup>1</sup> , S.C. Park <sup>1</sup> , V. Sukumaran <sup>2</sup> , <sup>1</sup> Seoul National University, Republic of Korea, <sup>2</sup> Periyar Maniammai University, India
[P2.39]	<b>Evaluation of efficacy of a sonicated trivalent avian colibacillosis vaccine, as an alum-precipitated vaccine, for the prevention of colisepticemia in broiler chickens</b> Z. Rajabi <sup>*1</sup> , T.Z. Salehi <sup>1</sup> , <sup>1</sup> University of Tabriz, Iran, <sup>2</sup> Microbiology Department, University of Tehran, Iran
[P2.40]	<b>Correlation between type I interferon response and protective efficacy of NS1-modified live attenuated influenza vaccine candidates</b> H. Jang*, J.M. Ngunjiri, C. Lee, The Ohio State University, USA
[P2.41]	<b>Evaluation of Salmonella Enteritidis LPS-deficient mutant as safe killed vaccine candidate for chickens</b> S.Y. Park*, Y.J. Cho, T-W. Hahn, C-H. Jung, B.K. Park, College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University, Chuncheon, 200-701, Republic of Korea
[P2.42]	<b>Immune responses to <i>Bordetella bronchiseptica</i> pertactin antigen delivered by live attenuated <i>Salmonella Enteritidis aroAompA</i> mutant vaccine in mice</b> K. Kim*, J.W. Yoon, T.W. Hahn, College of Veterinary Medicine, Republic of Korea
[P2.43]	<b>Novel PCV2 subunit vaccine induces cellular adaptive immunity in clinical protection</b> C-J. Chang*, I-H. Lai, Y-L. Lai, Y-A. Chen, Y-H. Chien, W-I. Chou, Reber Genetics Co., Ltd., Taiwan
[P2.44]	<b>Evaluation of the protective immunity of a virus-like particle (VLP) vaccine against infectious bronchitis virus (IBV) infection in chicken.</b> J.Y. Noh*, S.S. Yuk, J.H. Kwon, W.T. Hong, J.H. Jeong, S. Jeong, G.B. Gwon, C.S. Song, Konkuk University, Republic of Korea
[P2.45]	<b>Humoral immune response of avian reovirus vaccine with adjuvant and pre-immunostimulant.</b> W-T. Hong*, S-S. Yuk, E-O. Tsereen-Ochir, J-H. Kwon, J-Y. Noh, G-B. Gwon, S. Jeong, J-H. Jeong, C-S. Song, Konkuk University, Republic of Korea
[P2.47]	<b>A novel vaccine adjuvant improves the protection conferred by an avian influenza vaccine</b> F. Bertrand <sup>*1</sup> , J.B. Arous <sup>2</sup> , L. Dupuis <sup>2</sup> , <sup>1</sup> SEPPIC, China, <sup>2</sup> SEPPIC, France
[P2.48]	<b>Brucella abortus mutants are highly attenuated and confer long-term protective immunity against virulent B. abortus challenge</b> Q-L. Truong*, T-W. Hahn, Kangwon National University, Republic of Korea
[P2.49]	<b>Generation of an attenuated Salmonella-delivery system expressing adhesin and toxin antigens for pig pneumonic pasteurellosis and progressive atrophic rhinitis, and evaluation of its immune responses in a murine model</b> M.H. Shafiq, N.M. Kamble, J.H. Lee*, Chonbuk National University, Republic of Korea
[P2.50]	<b>Successful cross protective efficacy induced by heat-adapted live attenuated nephropathogenic infectious bronchitis virus derived from natural recombinant strain</b> S.S. Yuk*, T.H. Lim, H.N. Youn, J.H. Kwon, W.T. Hong, K.B. Kwon, C.S. Song, Konkuk University, Republic of Korea
[P2.51]	<b>Comparative full-length genome sequence analysis of live attenuated infectious bronchitis virus vaccine strain during long-term passage in embryonated chicken egg</b> J.H. Kwon*, D.H. Lee, T.O. Erdene-Ochir, J.K. Park, S.S. Yuk, J.Y. Noh, S.W. Choi, W.T. Hong, S.W. Lee, C.S. Song, Konkuk University, Republic of Korea
[P2.52]	<b>Schmallenberg virus deletion mutants are avirulent and protect cattle from virus challenge</b> K. Wernike*, F. Kraatz, S. Hechinger, P. König, H. Granzow, I. Reimann, M. Beer, Friedrich-Loeffler-Institut, Germany
[P2.53]	<b>Efficacy of a combined inactivated porcine reproductive and respiratory syndrome virus vaccine using North American and European strains in specific pathogen-free pigs</b> K.S. Lyoo <sup>*1</sup> , M. Yeom <sup>2</sup> , B.K. Kang <sup>3</sup> , D. Song <sup>2</sup> , B. Park <sup>4</sup> , <sup>1</sup> ChonBuk National University, Republic of Korea, <sup>2</sup> Korea University, Republic of Korea, <sup>3</sup> Green Cross Veterinary Products, Republic of Korea, <sup>4</sup> Seoul National University, Republic of Korea
[P2.54]	<b>Characterization of a novel inactivated <i>Salmonella Enteritidis</i> vaccine candidate generated using a modified cl857/<math>\lambda</math> P<sub>R</sub>/gene E expression system</b> S.Y. Park*, G.Y. Won, J.H. Lee, Chonbuk National University, Republic of Korea
[P2.55]	<b>Characterization of a <i>Salmonella Typhimurium</i> ghost carrying an adjuvant protein as a vaccine candidate for</b>

	<b>protection against virulent challenge</b> B.R. Kim, J.H. Kim, J.H. Lee*, <i>Chonbuk National University, Republic of Korea</i>
[P2.56]	<b>Transcriptomic analysis of MDV susceptible chicken embryonic stem (ES) derived cells</b> C. Jean <sup>1,2</sup> , G. Montillet <sup>1,2</sup> , A. Fuet <sup>1,2</sup> , C. Denesvre <sup>3</sup> , J. Franca <sup>1,2</sup> , C. Mazoyer <sup>1,2</sup> , S. Remy <sup>1,3</sup> , J-F. Vautherot <sup>1,3</sup> , B. Pain <sup>*1,2</sup> , <sup>1</sup> <i>INSERM, France</i> , <sup>2</sup> <i>INRA, France</i> , <sup>3</sup> <i>INRA, France</i>
[P2.57]	<b>Growth properties and vaccine efficacy of a new recombinant pseudorabies virus defective in both the glycoprotein E and thymidine kinase genes</b> C-Y. Wu <sup>*1</sup> , C-M. Liao <sup>2</sup> , M-S. Chien <sup>1</sup> , C. Huang <sup>1</sup> , <sup>1</sup> <i>National Chung Hsing Universit, Taiwan</i> , <sup>2</sup> <i>Bayer, Taiwan</i>
[P2.58]	<b>HPV Vaccination in Japan - troubling times</b> S.J.B. Hanley, <i>Hokkaido University, Japan</i>